Le Lézard
Classified in: Health
Subject: MISCELLANEOUS

JDRF welcomes CRA review of diabetes denials


TORONTO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- The 300,000+ Canadians and their families living with type 1 diabetes (T1D) across the country welcome today's announcement that the Government of Canada and the Canada Revenue Agency (CRA) will rescind new letters introduced in May that made it virtually impossible for adults with T1D to qualify for the disability tax credit (DTC). CRA has also committed to review all applications denied under the post-May 2017 process.

In collaboration with JDRF and Diabetes Canada, members of the T1D community rallied together this past month to express their outrage and disappointment over a decision that would not only have severely impacted their quality of life, but also put at risk the hard-earned savings they'd invested in Registered Disability Savings Plans (RDSPs).

Type 1 diabetes is a 24-7, chronic, progressive, autoimmune disorder that can neither be avoided nor cured. It renders those living with the disease dependent on insulin injections or infusions for the rest of their life, and puts patients at significant risk of complications such as heart disease, blindness, kidney failure, amputation and premature death.

Many Canadians with T1D who were previously approved for the DTC had suddenly been denied since May 2. They had been informed by the CRA that they would have to close their Registered Disability Savings Plans (RDSP) and faced repaying the government contributions to those accounts.

"This announcement shows that there is strength in numbers, and that together we can bring forth positive change that can have a tremendous impact on the lives of people living with T1D," says Dave Prowten, President and CEO of JDRF. "We look forward to working with the new Disability Advisory Committee to further improve the administration of the DTC and ensure those with T1D continue to have access to this important tax relief." 

JDRF will continue to follow this process closely and will continue to advocate for all those living with type 1 diabetes.

About JDRF

JDRF is the leading global organization funding T1D research. Our goal is to raise funds to support the most advanced international T1D research and progressively remove the impact of this disease from people's lives ? until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. JDRF is the largest charitable supporter of T1D research. For more information, please visit jdrf.ca.

Media Contact

Jessica Diniz
VP, Marketing & Development, JDRF Canada
[email protected]
647.789.2021


These press releases may also interest you

at 00:39
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...

25 avr 2024
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...

25 avr 2024
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

25 avr 2024
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

25 avr 2024
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...



News published on and distributed by: